These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 35932095)

  • 1. Predictors of serious adverse events and non-response in cirrhotic patients with primary biliary cholangitis treated with obeticholic acid.
    De Vincentis A; D'Amato D; Cristoferi L; Gerussi A; Malinverno F; Lleo A; Colapietro F; Marra F; Galli A; Fiorini C; Coco B; Brunetto M; Niro GA; Cotugno R; Saitta C; Cozzolongo R; Losito F; Giannini EG; Labanca S; Marzioni M; Marconi G; Morgando A; Pellicano R; Vanni E; Cazzagon N; Floreani A; Chessa L; Morelli O; Muratori L; Pellicelli A; Pompili M; Ponziani F; Tortora A; Rosina F; Russello M; Cannavò M; Simone L; Storato S; Viganò M; Abenavoli L; D'Antò M; De Gasperi E; Distefano M; Scifo G; Zolfino T; Calvaruso V; Cuccorese G; Palitti VP; Sacco R; Bertino G; Frazzetto E; Alvaro D; Mulinacci G; Palermo A; Scaravaglio M; Terracciani F; Galati G; Ronca V; Zuin M; Claar E; Izzi A; Picardi A; Invernizzi P; Vespasiani-Gentilucci U; Carbone M;
    Liver Int; 2022 Nov; 42(11):2453-2465. PubMed ID: 35932095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world experience with obeticholic acid in patients with primary biliary cholangitis.
    D'Amato D; De Vincentis A; Malinverno F; Viganò M; Alvaro D; Pompili M; Picciotto A; Palitti VP; Russello M; Storato S; Pigozzi MG; Calvaruso V; De Gasperi E; Lleo A; Castellaneta A; Pellicelli A; Cazzagon N; Floreani A; Muratori L; Fagiuoli S; Niro GA; Feletti V; Cozzolongo R; Terreni N; Marzioni M; Pellicano R; Pozzoni P; Baiocchi L; Chessa L; Rosina F; Bertino G; Vinci M; Morgando A; Vanni E; Scifo G; Sacco R; D'Antò M; Bellia V; Boldizzoni R; Casella S; Omazzi B; Poggi G; Cristoferi L; Gerussi A; Ronca V; Venere R; Ponziani F; Cannavò M; Mussetto A; Fontana R; Losito F; Frazzetto E; Distefano M; Colapietro F; Labanca S; Marconi G; Grassi G; Galati G; O'Donnell SE; Mancuso C; Mulinacci G; Palermo A; Claar E; Izzi A; Picardi A; Invernizzi P; Carbone M; Vespasiani-Gentilucci U;
    JHEP Rep; 2021 Apr; 3(2):100248. PubMed ID: 33681748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Greater Transplant-Free Survival in Patients Receiving Obeticholic Acid for Primary Biliary Cholangitis in a Clinical Trial Setting Compared to Real-World External Controls.
    Murillo Perez CF; Fisher H; Hiu S; Kareithi D; Adekunle F; Mayne T; Malecha E; Ness E; van der Meer AJ; Lammers WJ; Trivedi PJ; Battezzati PM; Nevens F; Kowdley KV; Bruns T; Cazzagon N; Floreani A; Mason AL; Parés A; Londoño MC; Invernizzi P; Carbone M; Lleo A; Mayo MJ; Dalekos GN; Gatselis NK; Thorburn D; Verhelst X; Gulamhusein A; Janssen HLA; Smith R; Flack S; Mulcahy V; Trauner M; Bowlus CL; Lindor KD; Corpechot C; Jones D; Mells G; Hirschfield GM; Wason J; Hansen BE;
    Gastroenterology; 2022 Dec; 163(6):1630-1642.e3. PubMed ID: 36150526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and safety of obeticholic acid in a Southern European multicentre cohort of patients with primary biliary cholangitis and suboptimal response to ursodeoxycholic acid.
    Gomez E; Garcia Buey L; Molina E; Casado M; Conde I; Berenguer M; Jorquera F; Simón MA; Olveira A; Hernández-Guerra M; Mesquita M; Presa J; Costa-Moreira P; Macedo G; Arenas JI; Manuel Sousa J; Ampuero J; Morillas RM; Santos A; De Carvalho A; Uriz J; Carrión JA; Luisa Gutiérrez M; Pérez-Fernández E; Fernández-Rodríguez CM;
    Aliment Pharmacol Ther; 2021 Feb; 53(4):519-530. PubMed ID: 33314220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of fibrates with obeticholic acid is able to normalise biochemical liver tests in patients with difficult-to-treat primary biliary cholangitis.
    Soret PA; Lam L; Carrat F; Smets L; Berg T; Carbone M; Invernizzi P; Leroy V; Trivedi P; Cazzagon N; Weiler-Normann C; Alric L; Rosa-Hezode I; Heurgué A; Cervoni JP; Dumortier J; Potier P; Roux O; Silvain C; Bureau C; Anty R; Larrey D; Levy C; Pares A; Schramm C; Nevens F; Chazouillères O; Corpechot C
    Aliment Pharmacol Ther; 2021 May; 53(10):1138-1146. PubMed ID: 33764590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination therapy of obeticholic acid and ursodeoxycholic acid in patients with primary biliary cholangitis who respond incompletely to ursodeoxycholic acid: a systematic review.
    Li X; Liao M; Pan Q; Xie Q; Yang H; Peng Y; Li Q; Qu J; Chai J
    Eur J Gastroenterol Hepatol; 2020 Sep; 32(9):1116-1122. PubMed ID: 32649329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Obeticholic acid improves hepatic bile acid excretion in patients with primary biliary cholangitis.
    Kjærgaard K; Frisch K; Sørensen M; Munk OL; Hofmann AF; Horsager J; Schacht AC; Erickson M; Shapiro D; Keiding S
    J Hepatol; 2021 Jan; 74(1):58-65. PubMed ID: 32717289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis.
    Nevens F; Andreone P; Mazzella G; Strasser SI; Bowlus C; Invernizzi P; Drenth JP; Pockros PJ; Regula J; Beuers U; Trauner M; Jones DE; Floreani A; Hohenester S; Luketic V; Shiffman M; van Erpecum KJ; Vargas V; Vincent C; Hirschfield GM; Shah H; Hansen B; Lindor KD; Marschall HU; Kowdley KV; Hooshmand-Rad R; Marmon T; Sheeron S; Pencek R; MacConell L; Pruzanski M; Shapiro D;
    N Engl J Med; 2016 Aug; 375(7):631-43. PubMed ID: 27532829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis.
    Kowdley KV; Vuppalanchi R; Levy C; Floreani A; Andreone P; LaRusso NF; Shrestha R; Trotter J; Goldberg D; Rushbrook S; Hirschfield GM; Schiano T; Jin Y; Pencek R; MacConell L; Shapiro D; Bowlus CL;
    J Hepatol; 2020 Jul; 73(1):94-101. PubMed ID: 32165251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Obeticholic acid for the treatment of primary biliary cholangitis.
    Ali AH; Lindor KD
    Expert Opin Pharmacother; 2016 Sep; 17(13):1809-15. PubMed ID: 27468093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of obeticholic acid in liver disease-A systematic review and meta-analysis.
    Kulkarni AV; Tevethia HV; Arab JP; Candia R; Premkumar M; Kumar P; Sharma M; Reddy DN; Padaki NR
    Clin Res Hepatol Gastroenterol; 2021 May; 45(3):101675. PubMed ID: 33722778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Obeticholic Acid and Fibrates in Primary Biliary Cholangitis: Comparative Effects in a Multicentric Observational Study.
    Reig A; Álvarez-Navascués C; Vergara M; Gómez-Domínguez E; Gallego-Moya A; Pérez-Medrano IM; Fábrega E; Hernández-Guerra M; Berenguer M; Estevez P; Arencibia A; Morillas RM; Horta D; Albillos A; Casado M; De la Cruz G; Fernandez-Bonilla E; Molina E; Hijona L; Diago M; Fernández-Rodriguez CM; González-Santiago JM; Sala M; Gómez-Camarero J; Romero-Gomez M; Suárez F; Vargas V; Ferre-Aracil C; Andrade RJ; Chahri N; Parés A
    Am J Gastroenterol; 2021 Nov; 116(11):2250-2257. PubMed ID: 34158466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid.
    Hirschfield GM; Mason A; Luketic V; Lindor K; Gordon SC; Mayo M; Kowdley KV; Vincent C; Bodhenheimer HC; Parés A; Trauner M; Marschall HU; Adorini L; Sciacca C; Beecher-Jones T; Castelloe E; Böhm O; Shapiro D
    Gastroenterology; 2015 Apr; 148(4):751-61.e8. PubMed ID: 25500425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis.
    Kowdley KV; Luketic V; Chapman R; Hirschfield GM; Poupon R; Schramm C; Vincent C; Rust C; Parés A; Mason A; Marschall HU; Shapiro D; Adorini L; Sciacca C; Beecher-Jones T; Böhm O; Pencek R; Jones D;
    Hepatology; 2018 May; 67(5):1890-1902. PubMed ID: 29023915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response Rate and Impact on Lipid Profiles of Obeticholic Acid Treatment for Patients with Primary Biliary Cholangitis: A Meta-Analysis.
    Gao Y; Li L; Li B; Zhan Y
    Can J Gastroenterol Hepatol; 2021; 2021():8829510. PubMed ID: 33511089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Obeticholic acid Exposure on Decompensation and Mortality in Primary Biliary Cholangitis and Cirrhosis.
    John BV; Schwartz K; Levy C; Dahman B; Deng Y; Martin P; Taddei TH; Kaplan DE
    Hepatol Commun; 2021 Aug; 5(8):1426-1436. PubMed ID: 34430786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term clinical impact and cost-effectiveness of obeticholic acid for the treatment of primary biliary cholangitis.
    Samur S; Klebanoff M; Banken R; Pratt DS; Chapman R; Ollendorf DA; Loos AM; Corey K; Hur C; Chhatwal J
    Hepatology; 2017 Mar; 65(3):920-928. PubMed ID: 27906472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of primary biliary cholangitis prior to obeticholic acid availability.
    Durazzo M; Bonetto S; Fagoonee S; Morgando A; Pellicano R
    Minerva Med; 2018 Dec; 109(6):410-417. PubMed ID: 30022645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Obeticholic acid-a new therapy in PBC and NASH.
    Chapman RW; Lynch KD
    Br Med Bull; 2020 May; 133(1):95-104. PubMed ID: 32282030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines.
    Hirschfield GM; Dyson JK; Alexander GJM; Chapman MH; Collier J; Hübscher S; Patanwala I; Pereira SP; Thain C; Thorburn D; Tiniakos D; Walmsley M; Webster G; Jones DEJ
    Gut; 2018 Sep; 67(9):1568-1594. PubMed ID: 29593060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.